宁乡花猪原代和第一代血液生理生化指标比较

目的比较原代宁乡花猪与其第一代仔猪血液生理生化指标的变化。方法常规方法测定宁乡花猪F0代16头,F1代16头血液18项生理指标和13项生化指标。结果F0代与F1代部分血液生理指标如白细胞（WBC）、红细胞（RBC）、血红蛋白（HGB）、红细胞积压（HCT）等13项有显著性差异（P〈0．05）;部分血液生化指标如总胆红素（TBIL）,尿素氮（BUN）,总蛋白（TP）,白／球蛋白（ALB／GLB）,葡萄糖（GLU）,有显著性差异（P〈0．05）;其他指标均无统计学差异。结论2代宁乡花猪之间部分血液生理生化指标有显著性差异。得到的数据可以为实验动物化研究提供相应的基础生理参考数据。     

不同氮素供应下水稻酚类物质代谢关键酶基因差异表达

运用实时荧光定量PCR技术探讨了不同供氮条件下强化感与弱化感水稻苯丙烷代谢途径中9个关键酶基因的表达差异。结果表明,与正常氮素供应相比,低氮胁迫引起强化感水稻‘P1312777’中与酚类代谢途径相关的9个关键酶基因表达量均上调,表达量增幅在1.9～5.4倍之间,且以PAL基因上调倍数最大。而弱化感水稻‘Lemont’则相反,只有2个基因(苯丙氨酸裂解酶基因和肉桂酰CoA基因)表达上调,但上调倍数分别是强化感水稻对应的基因的22%和74%,其余的7个基因表达均下调,降幅在29%～72%之间,表明低氮胁迫诱发的水稻化感抑草能力增强与其体内酚类物质合成代谢增强有关。     

水稻转录因子OsBP-73靶基因的初步筛选

OsBP-73是用酵母单杂交系统,以水稻蜡质基因(Wx)的顺式作用元件为诱饵,从水稻cDNA表达文库中筛选获得的转录因子。本文以OsBP-73基因为例介绍了用"下拉"(pull-down)方法筛选转录因子靶基因的一般步骤。将含有该基因DNA结合功能域的cDNA片段构建到原核表达载体上,并在大肠杆菌中诱导表达获得其蛋白p73。用纯化后的p73蛋白通过"下拉"实验对OsBP-73靶基因进行初步筛选,获得了22个阳性克隆,为进一步研究转录因子OsBP-73参与的水稻转录调控网络提供依据。     

我国高校人力资源开发的问题及其对策

分析了当前我国高校人力资源开发的重要性和存在的主要问题,并运用现代管理理论,提出了树立以人为本的管理理念、建立有利于人才成长的机制、运用柔性化管理模式的措施来促进我国高校人力资源的进一步开发利用。     

用RFLP标记剖析水稻穗颈维管束及穗部性状的遗传基础

采用籼、粳亚种间杂种F1(圭630×02428)花药培养获得的DH群体,对水稻穗颈大、小维管束数和倒数第2节间大、小维管束数等4个维管束性状,以及一、二次枝梗数,每穗颖花数3个穗部性状进行QTL分析,共检测到16个QTLs,其中有7个QTLs的加性效应较大,单个QTL的贡献率在20%以上。发现有4个QTLs成簇分布于第1染色体从RZ776到C11的大约35cM的区段上,来源于亲本"圭630"的这一染色体区段对穗颈大维管束、第2节间大维管束、第2节间小维管束和二次枝梗数4个性状的表达均具有增效作用。还讨论了利用分子标记辅助选择聚合增效QTLs、实现穗颈维管束性状遗传改良的策略。     

关于物种濒危等级标准之探讨--对IUCN物种濒危等级的思考

为了保存地球上的生物多样性,我们需要根据物种的种群数量与分布、种群数量波动与分布区下降速率来评定濒危物种的濒危等级,并针对物种的濒危等级提出具体的保护措施。1994年11月,IUCN第40次理事会会议正式通过了经过修订的Mace-Lande物种濒危等级标准作为IUCN物种濒危等级标准。IUCN濒危物种红色名录虽然不是国际法和国家法律,但是对于政府间组织、非政府组织的保护决策以及各国的自然法律法规的制定有着深远的影响,在保护生物学理论研究中也发挥了一定作用。我们在研究制定中国水生野生生物濒危等级标准时发现,如果直接应用IUCN物种濒危等级标准评定水生野生生物濒危等级将存在一些问题。如：(1)如何区别对待那些本来就数量稀少、分布区狭窄的物种和那些由于人类活动而导致其种群数量与生境面积急剧下降的物种?(2)不同的动物类群能否应用同一濒危标准尺度?(3)如何区别对待物种边缘分布区和核心分布区的种群数量与密度的差异?(4)如何处理种群的局部灭绝、局部濒危?(5)一些濒危物种在野生环境中濒危,但是这些物种可以人工繁殖,如何处理可以人工繁殖的濒危物种?(6)如果没有种群与栖息地的精确历史资料和统计数据,怎样应用物种的濒危标准评估其濒危等级?在实践中,我们针对这些问题提出了解决方案。考虑与国际流行的IUCN物种濒危等级标准接轨,我们提出来一个由“无危”、“值得关注”、“受胁”、“濒危”和“灭绝”等5个级构成的濒危等级系统,其中“值得关注”、“受胁”、“濒危”又分为“一般”与“高度”两个亚等级。我们提出应区分“生态濒危物种”、“进化濒危物种”;对于不同生物类群,应区分物种的生活史对策,制定不同生活史物种的濒危标准。对于r-对策物种,引入“经济灭绝”这一等级,将这一等级对应于“受胁”等级,以解决缺少物种数量的统计数据和历史数据这一难题;区别对待特有物种,将其濒危等级提升一等;引进集合种群(metapopulation)概念,将集合种群的局域种群(local population)作为“个体”对待。     

Report of a Scientific Working Group on Serious Adverse Events following Mectizan<Superscript>®</Superscript> treatment of onchocerciasis in <Emphasis Type="Italic">Loa loa</Emphasis> endemic areas

The occurrence of Serious Adverse Experiences (SAEs) following Mectizan^® treatment of onchocerciasis in Loa loa endemic areas has been increasingly reported over the past decade. These SAEs include a severely disabling, and potentially fatal, encephalopathy, which appears to correlate with a high load of L. loa microfilariae (> 30,000 mf/ml).Previous consultations organized by the Mectizan^® Donation Program (MDP) in 1995 and 1999 have developed useful "case" definitions of encephalopathic SAEs following Mectizan^® treatment and have summarized available evidence on its pathogenesis and optimal clinical management. At both meetings, the need for better understanding of the pathogenesis of the encephalopathy was emphasized, including the need for biological and autopsy specimens from the affected cases.Following a recommendation at the Joint Action Forum of the African Programme for Onchocerciasis Control in December 2001, the MDP, on behalf of the Mectizan^® Expert Committee, organized a Scientific Working Group on L. loa associated SAEs following Mectizan^® treatment in May 2002. The present report includes the background, new evidence, conclusions and recommendations from that Scientific Working Group. The following points represent a summary of the present status:1. Although there are more and better quality clinical and epidemiological data on L. loa, the pathogenesis of the Mectizan^®-related L. loa encephalopathy remains obscure.2. Very limited progress has been made in research on the pathogenesis of encephalopathy, because of the lack of specimens from cases, and the lack of animal models.3. There has been no particular breakthrough in terms of the medical management of patients with L. loa encephalopathy; however, a favorable outcome usually results from prompt general nursing and nutritional care which remain the major interventions.The main recommendations for future actions are as follows:1. Validate and update the mapping of L. loa with a combination of remote sensing and RAPLOA techniques.2. Conduct an expert analysis of the apparent clustering of encephalopathic SAEs reported so far.3. Investigate a possible "pre-treatment" scheme with high-dose albendazole in L. loa endemic communities at high risk of encephalopathic SAEs if treated with Mectizan^®; this study will be conducted in collaboration with WHO/TDR.4. Establish a post of Loiasis Technical Advisor for research and operational support in Cameroon, to conduct population surveys and to facilitate better data collection from SAE cases, including postmortem studies as appropriate.5. Investigate the possibility of developing an animal model of L. loa encephalopathy; this activity would be linked to the above-mentioned research agenda in Cameroon.6. Investigate the best care model for encephalopathic SAEs, including identification of early warning signs and therapeutic interventions.7. Develop further models for health education messages needed for community compliance with Mectizan^® treatment, and family support for SAE cases.8. Conduct research studies on the safety of combination therapy of Mectizan^® and albendazole in areas co-endemic for L. loa and lymphatic filariasis (LF) with coordination from the relevant technical bodies that oversee these issues.The above recommendations will be implemented through a continuing collaboration between the interested parties represented at the Scientific Working Group, involved in onchocerciasis control and/or the Global Programme to Eliminate Lymphatic Filariasis.     

The generation and characterization of antagonist RNA aptamers to human oncostatin M

Oncostatin M (OSM) is a multifunctional member of the interleukin-6 cytokine family. OSM has been implicated as a powerful proinflammatory mediator and may represent a potentially important, novel therapeutic opportunity for treatment of established rheumatoid arthritis. To further investigate the role of OSM in inflammatory disorders, we have isolated a series of RNA aptamers that bind specifically to human OSM. The highest affinity aptamer, designated ADR58, has been characterized in a series of in vitro and cell based assays. ADR58 has an affinity of 7 nm for human OSM, and it can antagonize OSM binding to the gp130 receptor and specifically antagonize OSM mediated signaling. The aptamer has been truncated in length to 33 bases, all pyrimidine positions are substituted with 2' fluorine, and 14 of 18 purine positions have been substituted with 2' O-methyl to increase stability toward nucleases. This truncated, modified form of ADR58 retains complete affinity and functional activity for OSM. This aptamer may be used as a tool to further investigate the role of OSM in inflammatory disorders and may also have role as a therapeutic agent.